N-Ethylnorketamine |
|
| ATC code | |
|---|
|
| Legal status |
|
|---|
|
2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| CompTox Dashboard (EPA) | |
|---|
|
| Formula | C14H18ClNO |
|---|
| Molar mass | 251.75 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
Clc2ccccc2C1(NCC)CCCCC1=O
|
InChI=1S/C14H18ClNO/c1-2-16-14(10-6-5-9-13(14)17)11-7-3-4-8-12(11)15/h3-4,7-8,16H,2,5-6,9-10H2,1H3 Key:ITBBBZIIFJJMDU-UHFFFAOYSA-N
|
N-Ethylnorketamine (ethketamine, NENK, 2-Cl-2'-Oxo-PCE) is a designer drug which is presumed to have similar properties to ketamine, a dissociative anesthetic drug with hallucinogenic and sedative effects. It has been sold over the internet since around September 2012, and identified in seized drug samples by analytical laboratories in the UK and other European countries.[1]
It is an NMDA receptor antagonist. In mice its antidepressant effects are dependent on activation of AMPA and 5-HT2 receptors, as blocking those abolishes said activity.[2]
Legal Status
As of October 2015 NENK is a controlled substance in the United Kingdom,[3] China,[4] and the US state of Alabama.[5]
References
- ^ Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine Report (2012)
- ^ Sayson LV, Botanas CJ, Custodio RJ, Abiero A, Kim M, Lee HJ, et al. (July 2019). "The novel methoxetamine analogs N-ethylnorketamine hydrochloride (NENK), 2-MeO-N-ethylketamine hydrochloride (2-MeO-NEK), and 4-MeO-N-ethylketamine hydrochloride (4-MeO-NEK) elicit rapid antidepressant effects via activation of AMPA and 5-HT2 receptors". Psychopharmacology. 236 (7): 2201–2210. doi:10.1007/s00213-019-05219-x. PMID 30891619. S2CID 253743164.
- ^ Explanatory Memorandum to the Misuse of Drugs (1971) Amendment Order 2013
- ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
- ^ "Alabama Senate Bill 333 - Controlled substances, Schedule I, additional synthetic controlled substances and analogue substances included in, trafficking in controlled substance analogues, requisite weight increased, Secs. 13A-12-231, 20-2-23 am'd". March 2014. Retrieved 28 September 2015.
|
|---|
Psychedelics (5-HT2AR agonists) |
- Tryptamines (e.g., DMT, psilocin, psilocybin, bufotenin, 5-MeO-DMT, AMT)
- Phenethylamines (e.g., mescaline, 2C-B, DOM, MDA, TMA, 2C-B-FLY, 25I-NBOMe)
- Lysergamides (e.g., LSD, ergine, isoergine)
- Others (e.g., quipazine, efavirenz)
- For a full list of serotonergic psychedelics, see the navbox here and the list here instead.
|
|---|
Dissociatives (NMDAR antagonists) | |
|---|
Deliriants (mAChR antagonists) | |
|---|
Cannabinoids (CB1R agonists) | |
|---|
| κOR agonists | |
|---|
| GABAAR agonists | |
|---|
Inhalants (mixed MoATooltip mechanism of action) |
- Aliphatic hydrocarbons
- Butane
- Gasoline
- Kerosene
- Propane
- Aromatic hydrocarbons
- Ethers
- Haloalkanes
|
|---|
| Others |
- Aminochromes (e.g., adrenochrome, adrenolutin)
- Carbogen
- Certain GABAA receptor positive allosteric modulators (nonbenzodiazepines/Z-drugs) (e.g., eszopiclone, zaleplon, zolpidem, zopiclone)
- CI-966
- Cryogenine
- Glaucine
- Hallucinogenic bolete mushrooms (e.g., Lanmaoa asiatica)
- Harmala alkaloids/β-carbolines (e.g., harmaline, 6-methoxyharmalan)
- Iboga alkaloids/azepinoindoles (e.g., ibogaine)
- Isoaminile
- Noscapine
- Nutmeg (e.g., myristicin, elemicin)
- Oneirogens (e.g., Calea zacatechichi, galantamine, nicotine, Silene capensis)
- Prenoxdiazine
- Pukateine
|
|---|
|
|
|---|
|
|---|
| AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor | |
|---|
| KARTooltip Kainate receptor | |
|---|
| NMDARTooltip N-Methyl-D-aspartate receptor | |
|---|
- See also: Receptor/signaling modulators
- Metabotropic glutamate receptor modulators
- Glutamate metabolism/transport modulators
|
|
|---|
| Group I | | mGluR1Tooltip Metabotropic glutamate receptor 1 | |
|---|
| mGluR5Tooltip Metabotropic glutamate receptor 5 | |
|---|
|
|---|
| Group II | | mGluR2Tooltip Metabotropic glutamate receptor 2 | |
|---|
| mGluR3Tooltip Metabotropic glutamate receptor 3 | |
|---|
|
|---|
| Group III | | mGluR4Tooltip Metabotropic glutamate receptor 4 |
- Antagonists: CPPG
- MAP4
- MPPG
- MSOP
- MTPG
- UBP-1112
|
|---|
| mGluR6Tooltip Metabotropic glutamate receptor 6 |
- Antagonists: CPPG
- MAP4
- MPPG
- MSOP
- MTPG
- UBP-1112
|
|---|
| mGluR7Tooltip Metabotropic glutamate receptor 7 |
- Antagonists: CPPG
- MAP4
- MMPIP
- MPPG
- MSOP
- MTPG
- UBP-1112
- XAP044; Negative allosteric modulators: ADX71743
|
|---|
| mGluR8Tooltip Metabotropic glutamate receptor 8 |
- Antagonists: CPPG
- MAP4
- MPPG
- MSOP
- MTPG
- UBP-1112
|
|---|
|
|---|
See also: Receptor/signaling modulators • Ionotropic glutamate receptor modulators • Glutamate metabolism/transport modulators |
|